Tesamorelin Dosage Guide: FDA Protocol, Visceral Fat Results, and Timeline

Tesamorelin Dosage Guide: FDA Protocol, Visceral Fat Results, and Timeline

Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus that significantly increases stability and potency compared to endogenous GHRH and other GHRH analogs like sermorelin.

It is FDA-approved under the brand name Egrifta (tesamorelin for injection) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — a condition characterized by severe visceral fat accumulation as a side effect of antiretroviral therapy. This FDA approval, backed by rigorous Phase 3 clinical trials, makes tesamorelin one of only two GHRH analogs with proven efficacy in reducing visceral adiposity (the other being the off-label use of growth hormone itself).

Tesamorelin vs. Other GHRH Analogs

Understanding where tesamorelin fits within the GHRH peptide family is important for dosing context:

| Peptide | Half-life | Potency | FDA Status | Primary Use | |---------|-----------|---------|-----------|-------------| | Sermorelin | ~10 min | Low | Approved (pediatric dx) | Anti-aging, GH deficiency | | CJC-1295 no-DAC | ~30 min | Moderate | Research | Body comp, recovery | | Tesamorelin | ~38 min | High | Approved (HIV lipodystrophy) | Visceral fat reduction | | CJC-1295 DAC | 6–8 days | High (sustained) | Research | Convenience, sustained GH |

Tesamorelin's N-terminal modification significantly extends its biological half-life compared to sermorelin and provides greater receptor binding affinity at GHRH receptors. This translates to greater GH stimulation per injection and more reliable IGF-1 elevation.

FDA-Approved Tesamorelin Dosage

The FDA-approved protocol is the most rigorously validated dosing regimen available for any GHRH peptide:

FDA-approved dose: 2 mg subcutaneous injection once daily Route: Subcutaneous injection into the abdomen Duration: Minimum 26 weeks to assess efficacy; continued use if response is maintained Discontinuation: If visceral adiposity does not improve by 26 weeks, reconsider therapy

This 2 mg daily dose was established in two pivotal Phase 3 clinical trials (LIPO-010 and LIPO-011) that enrolled over 800 HIV patients. The clinical trial data represents the most robust human evidence for any GHRH peptide protocol.

Off-Label and Research Dosing

For non-HIV-lipodystrophy applications (general visceral fat reduction, body composition optimization, anti-aging), practitioners use the same 2 mg daily dose given its strong clinical validation:

Standard off-label dose:

• 2 mg/day SubQ (matches FDA protocol)

Conservative dose (anti-aging, general use):

• 1–1.5 mg/day SubQ
• Appropriate for those primarily seeking anti-aging GH benefits with less aggressive visceral fat reduction

Timing note: Some practitioners time the injection in the morning fasted state (paralleling other GH peptides) for maximum GH pulse. The FDA-approved timing is once daily without specific timing restrictions, as tesamorelin's half-life of ~38 minutes followed by sustained IGF-1 elevation means the timing of injection relative to meals has less dramatic impact than with shorter-acting peptides.

Injection Site: Subcutaneous Abdomen

The FDA protocol specifies abdominal subcutaneous injection, and this is clinically and mechanistically important for visceral fat applications:

Why abdomen?

• Proximity to visceral and abdominal subcutaneous fat depots
• Optimal local peptide concentration in target tissue
• Consistent, well-vascularized absorption site

Injection technique (per Egrifta labeling):

1. Rotate sites within the abdomen; avoid navel and scar tissue
2. Use a small-gauge insulin syringe (27–30 gauge, 0.5 inch)
3. Pinch skin fold; insert at 45-degree angle
4. Inject slowly; withdraw needle and apply gentle pressure
5. Do not massage injection site

Alternate sites (off-label): Some practitioners also use thigh or upper arm for rotation when abdominal sites develop local reactions, though abdomen is preferred for targeted visceral fat reduction.

Reconstitution Protocol

Egrifta comes with a specific reconstitution protocol that should be followed precisely:

Supplied: Tesamorelin lyophilized powder + sterile water diluent (FDA product)

Research grade reconstitution:

• Tesamorelin vials typically 2 mg
• Add 2 mL bacteriostatic water = 1 mg/mL
• For 2 mg dose: draw 2 mL (200 units on U-100 syringe)
• For 1 mg dose: draw 1 mL

Important: Do not shake the vial. Gently roll or swirl to dissolve. Tesamorelin solution should be clear and colorless; discard if particulates are present.

Storage:

• Lyophilized: Refrigerate at 2–8°C; manufacturer recommends not freezing
• Reconstituted (research grade): Refrigerate; use within 21–28 days
• Protect from light; do not use if solution has been frozen after reconstitution

Visceral Fat Monitoring

Visceral adipose tissue (VAT) is the primary target of tesamorelin therapy. Monitoring VAT requires imaging:

Measurement methods:

• CT scan (gold standard): Cross-sectional imaging at L4–L5 level measures VAT area in cm²; most accurate but involves radiation
• MRI: Non-radiation alternative; equally accurate but more expensive
• DEXA scan: Can estimate regional fat distribution including truncal/abdominal fat; less specific to visceral vs. subcutaneous
• Waist circumference: Practical surrogate; correlates with VAT changes but less precise

Clinical trial results: The Phase 3 trials used CT measurement of VAT as the primary endpoint:

• Average VAT reduction: 18–20% reduction in VAT area at 26 weeks compared to placebo
• Responder definition: >8% reduction in VAT (used in trials to define meaningful response)
• Maintenance: Continued daily dosing required; VAT returns toward baseline when treatment stops

Monitoring schedule:

• Baseline: CT or DEXA before starting
• Week 13–16: Mid-protocol assessment (DXA or waist circumference)
• Week 26: Primary efficacy assessment (repeat CT or DXA)
• Ongoing: Every 6 months if continuing therapy

Blood Work Monitoring

Beyond visceral fat imaging, blood work monitoring is essential:

Primary markers:

• IGF-1: Rises with tesamorelin therapy; should be monitored to remain within normal range for age
• Fasting glucose: GH therapy mildly increases blood glucose; monitor every 3 months
• HbA1c: Every 6 months; more important in diabetic/pre-diabetic individuals
• Fasting insulin/HOMA-IR: GH has counter-regulatory effects on insulin; ensure insulin sensitivity is not deteriorating

IGF-1 targets: Same age-adjusted targets as for other GH peptides — upper quartile of normal range for age, not above normal range. Supratherapeutic IGF-1 is a signal to reduce dose.

Additional monitoring:

• PSA (men >40): Baseline and annually (GH/IGF-1 elevation may influence prostate tissue)
• Comprehensive metabolic panel: Liver enzymes, kidney function annually
• Thyroid panel: T3, T4, TSH (GH therapy increases T4-to-T3 conversion; hypothyroid individuals may need thyroid medication adjustment)

Expected Results and Timeline

The Phase 3 clinical trials provide the clearest evidence-based timeline for tesamorelin results:

Weeks 1–4:

• Early metabolic effects: improved energy, potential sleep benefits
• No measurable visceral fat change yet (too early)
• Some users report improved sense of wellbeing within 2–4 weeks

Weeks 4–12:

• IGF-1 begins to meaningfully rise (monitor at 6–8 weeks)
• Body composition changes begin — lean mass may increase slightly while fat mass starts to decline
• Waist circumference may show early reduction (1–2 cm)

Weeks 13–26:

• Primary period of visceral fat reduction
• Clinical trials show ~15–20% VAT reduction by week 26
• Improved body composition (more lean mass, less visceral fat)
• Possible improvements in lipids: HDL may increase, triglycerides may decrease
• Physical performance and recovery improvements

Beyond 26 weeks:

• Continued maintenance of results if therapy continues
• Visceral fat returns toward baseline within months of stopping
• Long-term treatment (1–2+ years) maintains benefits in compliant patients

Important: These results are mean values from clinical trial populations and individual response varies. Diet, exercise, and overall metabolic health significantly influence outcomes.

Cycling

The FDA-approved protocol does not specify cycling — tesamorelin is used continuously for as long as the patient is responding and benefits outweigh risks.

Off-label cycling approaches:

• 6 months on / 1–2 months off: Allows IGF-1 normalization and assessment of baseline
• Continuous use with quarterly monitoring: The approach used in HIV patients; appropriate for those with a specific medical indication
• Periodic use for body composition goals: 6-month protocol followed by a break and reassessment

The decision to cycle vs. continue should be guided by blood work (particularly IGF-1) and clinical assessment of ongoing benefit.

Side Effects

Tesamorelin's side effects are well-characterized from Phase 3 trials:

Common (>5% in clinical trials):

• Water retention/edema: Peripheral edema, particularly in lower extremities; usually resolves with continued use or dose reduction
• Arthralgia (joint pain): Common GH effect; usually mild and transient
• Myalgia (muscle aches): Especially in early weeks
• Peripheral neuropathy symptoms: Tingling, numbness (carpal tunnel-like); usually resolves

Metabolic effects (monitor):

• Mild glucose elevation: Mean fasting glucose rise of ~2–5 mg/dL in trials; generally clinically insignificant but monitor in diabetics
• Insulin resistance: Mild and reversible; GH counter-regulatory effect
• IGF-1 elevation: Must be monitored; dose reduction if above normal range

Uncommon but notable:

• Injection site reactions (erythema, pruritus, pain)
• Headache
• Facial flushing

Contraindications:

• Active malignancy or history of malignancy (IGF-1 elevation is pro-growth)
• Disruption of hypothalamic-pituitary axis (pituitary tumor, cranial irradiation)
• Pregnancy or breastfeeding
• Hypersensitivity to tesamorelin or mannitol (excipient)

Tesamorelin vs. AOD-9604 for Fat Loss

Both tesamorelin and AOD-9604 target visceral fat but through completely different mechanisms:

| Feature | Tesamorelin | AOD-9604 | |---------|-------------|----------| | Mechanism | GHRH → GH → IGF-1 | Direct adipocyte beta-3 activation | | IGF-1 effect | Significant elevation | None | | GH effect | Yes | No | | Anabolic effects | Yes (muscle sparing) | No | | Evidence level | Strong (Phase 3 trials) | Moderate (Phase 2) | | Cost | High | Moderate | | Dose | 2 mg/day | 300 mcg/day |

Tesamorelin is a more complete body recomposition agent — it reduces visceral fat while simultaneously supporting lean mass via GH/IGF-1 elevation. AOD-9604 is purely lipolytic with no anabolic component. Stacking both is theoretically additive for fat loss.

Frequently Asked Questions

Q: Is tesamorelin more effective than sermorelin for fat loss? Based on available evidence, yes. Tesamorelin has more potent GHRH receptor binding, a longer half-life, and Phase 3 clinical trial data specifically demonstrating significant visceral fat reduction. Sermorelin has a shorter half-life and is primarily used for anti-aging and GH optimization rather than targeted visceral fat reduction. For body composition goals, tesamorelin is the stronger GHRH peptide choice.

Q: Do I need to take tesamorelin every day? The FDA-approved protocol is daily injection. Because tesamorelin acts through GH (which declines rapidly between injections), the sustained daily dosing is important for maintaining the therapeutic GH elevation that drives visceral fat reduction. Some practitioners use 5 days on / 2 days off to reduce cost with potentially modest reduction in efficacy.

Q: Will visceral fat return when I stop tesamorelin? Yes. Clinical trials show that visceral fat returns toward baseline within 6–12 months of stopping tesamorelin. This is consistent with all GH-based therapies — the benefits are maintained only with continued use. This distinguishes tesamorelin from lifestyle-based fat loss, which is more durable.

Q: Can tesamorelin be used by non-HIV patients for visceral fat reduction? The FDA approval is specific to HIV-associated lipodystrophy. Off-label use in non-HIV patients with excess visceral fat does occur in anti-aging and metabolic medicine. The clinical trial evidence for efficacy in non-HIV visceral obesity is limited but mechanistically plausible, and several small studies have shown benefits in this population.

Q: How does tesamorelin interact with diabetes medications? Tesamorelin causes mild insulin resistance via GH elevation. In diabetic patients taking insulin or oral hypoglycemics, dose adjustments may be needed as blood glucose may rise slightly. Close glucose monitoring during the first 8–12 weeks of tesamorelin therapy is advisable for any patient with diabetes or pre-diabetes.

Q: Can I combine tesamorelin with ipamorelin? Yes. Combining tesamorelin (GHRH agonist) with ipamorelin (GHRP/ghrelin agonist) produces synergistic GH stimulation through dual receptor pathway activation. This combination provides strong GH elevation for both fat reduction and anabolic support, though IGF-1 must be monitored carefully.

---

This article is for informational purposes only. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Off-label use requires a physician's involvement. Consult a healthcare provider before beginning any peptide protocol.